Cover Image
市場調查報告書

Cebranopadol(神經病變性疼痛治療藥):市場預測與分析

Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 302380
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
Cebranopadol(神經病變性疼痛治療藥):市場預測與分析 Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022
出版日期: 2014年04月30日 內容資訊: 英文 85 Pages
簡介

Cebranopadol(GRT-6005)是Grunenthal為了治療輕度、重度疼痛而開發的小分子型Opioids(類鴉片物質)止痛藥。2010年12月,Grunenthal和Forest Laboratories簽下Cebranopadol及其持續性化合物GRT-6006相關的共同開發及銷售契約。這個藥劑目前正達到糖尿病疼痛性神經病變(PDN)相關臨床實驗的第Ⅱb階段,癌症性疼痛相關實驗第Ⅲ階段,慢性傷害性疼痛、膝關節炎造成的輕∼重度疼痛、慢性腰痛相關實驗第Ⅱ階段。

本報告提供神經病變性止痛藥之一──Cebranopadol的全球市場相關分析,彙整神經病變性疼痛概要和治療方法,競爭的企業·藥品概要,市場競爭概況,Cebranopadol的商品資訊(特色·功效·安全性等),全球主要國家的市場販售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 神經病變性疼痛臨床症狀:症狀
    • 糖尿病疼痛性神經病變(PDN)
    • 帶狀皰疹後神經痛(PHN)
    • 三叉神經痛(TN)
  • 病因與病情
    • 病因
    • 病理生理學

第4章 疾病的管理

  • 診斷·治療概要
    • 診斷
    • 治療的概要與指南

第5章 競爭企業的評估

  • 概要

第6章 未滿足需求與市場機會

  • 概要
  • 醫生的知識/認知度
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 診斷上的課題
  • 治療率低與過小量給藥
  • 藥物治療有效性及安全性不足
  • 高齡患者人口 - 藥物耐受性
  • 合理的/個人化醫療

第7章 開發平台評估

  • 概要
  • 臨床實驗中的有潛力的藥劑

第8章 關於Cebranopadol

  • 概要
  • 功效
  • 安全性
  • 給藥·劑型方法
  • 臨床方面·商業方面的潛在性地位
  • 價格設定和醫療費給付
  • SWOT分析
  • 預測

第9章 附錄

圖表一覽

目錄
Product Code: GDHC412DFR

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

Cebranopadol (GRT-6005) is a small-molecule opioid analgesic that is being developed by Grunenthal for the treatment of moderate to severe chronic pain conditions. In December 2010, Grunenthal entered into a licensing agreement with Forest Laboratories for the co-development and commercialization of cebranopadol and its follow-on compound, GRT-6006. The drug is currently in Phase IIb of clinical development for PDN, and is also in Phase III of development for cancer pain, as well as in Phase II for chronic nociceptive pain, moderate to severe pain due to osteoarthritis of the knee, and chronic low back pain.

Scope

  • Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Cebranopadol including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Cebranopadol for the top six countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Cebranopadol performance
  • Obtain sales forecast for Cebranopadol from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Clinical Manifestations of Neuropathic Pain - Signs and Symptoms
    • 3.1.1. Painful Diabetic Neuropathy
    • 3.1.2. Postherpetic Neuralgia
    • 3.1.3. Trigeminal Neuralgia
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Overview and Guidelines

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Physician Knowledge or Awareness
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Diagnostic Challenges
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Low Treatment Rate and Underdosing of Medications
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Unsatisfactory Efficacy and Safety Profiles of Pharmacological Treatments
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Elderly Patient Population - Drug Tolerability
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Rational or Personalized Therapies
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Cebranopadol

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical and Commercial Positioning
  • 8.6. Pricing and Reimbursement
  • 8.7. SWOT Analysis
  • 8.8. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed PDN, PHN, and TN Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Classification of NP Syndromes Based on the Site of Somatosensory Damage
  • Table 2: Signs and Symptoms of NP
  • Table 3: Screening Tools for NP
  • Table 4: NP-Related Signs and Symptoms
  • Table 5: Treatment Guidelines for NP
  • Table 6: Recommended Drug Therapies for NP Conditions by Line of Therapy
  • Table 7: Most Prescribed Drugs for NP by Indication and Line of Therapy in the Global Markets, 2012
  • Table 8: NNT and NNH for Classes of Oral Drugs used in NP Treatment, 2013
  • Table 9: Select Products Used for NP Treatment, 2013
  • Table 10: Unmet Need and Opportunity in NP
  • Table 11: NP - Promising Drugs in Clinical Development
  • Table 12: Comparison of Drugs in Development for NP, 2014
  • Table 13: Product Profile - Cebranopadol
  • Table 14: Cebranopadol SWOT Analysis, 2013
  • Table 15: Global Sales Forecasts ($) for Cebranopadol, 2012-2022

List of Figures

  • Figure 1: Nociceptive Versus Neuropathic Pain
  • Figure 2: Etiology and Pathophysiology of NP
  • Figure 3: Pain Pathway - Somatosensory System
  • Figure 4: Pathophysiological Mechanisms of NP at Different Levels of the Nervous System
  • Figure 5: Pathophysiological Targets of NP Drugs
  • Figure 6: NeuSPIG Diagnostic Certainty Algorithm for NP
  • Figure 7: General Treatment Algorithm for NP
  • Figure 8: Competitive Assessment of Mid-to-Late Stage Pipeline Agents in NP, 2012-2022
Back to Top